Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis

• Published in: Oncotarget Vol. 7; no. 15; pp. 19589 - 19600
• Main Authors: Hao, Mu, Zang, Meirong, Zhao, Lei, Deng, Shuhui, Xu, Yan, Qi, Fang, An, Gang, Qin, Yu, Sui, Weiwei, Li, Fei, Yang, Wenjuan, Li, Zengjun, Yi, Shuhua, Zou, Dehui, Zhan, Fenghuang, Qiu, Lugui
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 12.04.2016
• Subjects: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Bone Diseases - blood; Bone Diseases - etiology; Bone Diseases - genetics; Female; Gene Expression Profiling - methods; Humans; Kaplan-Meier Estimate; Male; MicroRNAs - blood; MicroRNAs - genetics; Middle Aged; Multiple Myeloma - blood; Multiple Myeloma - complications; Multiple Myeloma - genetics; Predictive Value of Tests; Prognosis; Research Paper; multiple myeloma; serum miRNAs; biomarkers; bone disease
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.7319

Multiple myeloma (MM) originates from malignant plasma cells, leading to multiple destructive lytic bone lesions that occur in more than 80% of MM patients. MicroRNAs have been reported to be involved in development of bone lesions in MM. However, the circulating microRNA as diagnostic and prognostic biomarkers for bone lesions has not been elucidated yet. In this study, we identified differentially expressed miRNAs that are potentially involved in myeloma-related bone disease in serum of MM patients. MiR-214 and miR-135b was shown to be increased in serum of MM patients with bone lesions. Serum level of miR-214 and miR-135b was highly correlated with the severity of lytic bone lesions and demonstrated as a diagnostic tool for identifying bone diseases based on results of a receiver operating characteristic analysis (ROC). In addition, patients with high levels of serum miR-214 had a dismal survival with significantly shortened progression free survival (PFS) and overall survival (OS). Interestingly, bisphosphonates treatment significantly extended PFS and OS in patients with higher level of miR-214 comparing to patients without bisphosphonates treatment. Taken together, our findings revealed the significance of circulating miR-214 and miR-135b levels in detection of bone disease and in prediction of prognosis of patients with multiple myeloma, suggesting its potential clinical applications. The result of this study also set the foundation for searching more circulating miRNA as biomarker for tumor bone lesions.